Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Olema Pharmaceuticals on Tuesday, setting a price target of $70, which is approximately 115.52% above the present share price of $32.48.
Yee expects Olema Pharmaceuticals to post earnings per share (EPS) of -$0.50 for the second quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Olema Pharmaceuticals, with an average price target of $62.5.
The analysts price targets range from a high of $70 to a low of $55.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$10.13 million. The company's market cap is $1.28 billion.
According to TipRanks.com, Jefferies analyst Michael Yee is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 5.1% and a 47.95% success rate.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.